/stocks — the workspaceLOADING
Abbott Laboratories spans four segments: medical devices, diagnostics, nutrition, and established pharmaceuticals sold outside the US. FreeStyle Libre glucose monitors anchor the devices business, while Similac, Ensure, and Pedialyte carry the nutrition line.
ABBOTT LABORATORIES (ABT) is a pharmaceutical preparations company. Piotroski F-Score 4/7. 22 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-07-16 from ABT's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
A plain-English read on ABT plus an auto-SWOT — built from ABT's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate ABT using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
| Stratton John GDirector | BUY | $174K | view → |
| STARKS DANIEL JDirector | BUY | $927K | view → |
| Boudreau Philip PEVP AND CFO | BUY | $201K | view → |
| Richard Dean McCormickU.S. Representative · NY-01 | BUY | $1,001 - $15,000 | filed 2026-07-09 |
| Rohit KhannaU.S. Representative · CA-17 | BUY | $1,001 - $15,000 | filed 2026-07-06 |
| Gilbert CisnerosU.S. Representative · CA-39 | BUY | $1,001 - $15,000 | filed 2026-07-02 |
| Julie JohnsonU.S. Representative · TX-32 | SELL | $1,001 - $15,000 | filed 2026-06-12 |
| Gilbert CisnerosU.S. Representative · CA-39 | SELL | $1,001 - $15,000 | filed 2026-06-08 |
| Richard W. AllenU.S. Representative · GA-12 | SELL | $15,001 - $50,000 | filed 2026-06-05 |
| GMO (Jeremy Grantham) | $914.9M | 2.3% of portfolio |
Projected from ABT's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment ABT files its announcement.
ABT has sold off after 5 of its last 8 earnings reports.
Earnings reactions have been moderate.
ABT has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+5.5% and -11.0%).
A more typical earnings reaction has been approximately ±4.5%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-04-16 | -4.7% |
| 2026-01-22 | -11.0% |
| 2025-10-15 | -4.2% |
| 2025-07-17 | -6.1% |
| 2025-04-16 | +3.8% |
| 2025-01-22 | +5.5% |
| 2024-10-16 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| +1.6% |
| 2024-07-18 | -2.5% |